Literature DB >> 27026707

The G Protein-Coupled Estrogen Receptor Agonist G-1 Inhibits Nuclear Estrogen Receptor Activity and Stimulates Novel Phosphoproteomic Signatures.

L Cody Smith1, Kimberly J Ralston-Hooper2, P Lee Ferguson2, Tara Sabo-Attwood3.   

Abstract

Estrogen exerts cellular effects through both nuclear (ESR1 and ESR2) and membrane-bound estrogen receptors (G-protein coupled estrogen receptor, GPER); however, it is unclear if they act independently or engage in crosstalk to influence hormonal responses. To investigate each receptor's role in proliferation, transcriptional activation, and protein phosphorylation in breast cancer cells (MCF-7), we employed selective agonists for ESR1 propyl-pyrazole-triol (PPT), ESR2 diarylpropionitrile (DPN), and GPER (G-1) and also determined the impact of xenoestrogens bisphenol-A (BPA) and genistein on these effects. As anticipated, 17β-estradiol (E2), PPT, DPN, BPA, and genistein each enhanced proliferation and activation of an ERE-driven reporter gene whereas G-1 had no significant impact. However, G-1 significantly reduced E2-, PPT-, DPN-, BPA-, and genistein-induced proliferation and ERE activation at doses greater than 500 nM indicating that G-1 mediated inhibition is not ESR isotype specific. As membrane receptors initiate cascades of phosphorylation events, we performed a global phosphoproteomic analysis on cells exposed to E2 or G-1 to identify potential targets of receptor crosstalk via downstream protein phosphorylation targets. Of the 211 phosphorylated proteins identified, 40 and 13 phosphoproteins were specifically modified by E2 and G-1, respectively. Subnetwork enrichment analysis revealed several processes related to cell cycle were specifically enriched by G-1 compared with E2. Further there existed a number of newly identified proteins that were specifically phosphorylated by G-1. These phosphorylation networks highlight specific proteins that may modulate the inhibitory effects of G-1 and suggest a novel role for interference with nuclear receptor activity driven by E2 and xenoestrogens.
© The Author 2016. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  G-1; GPER; estrogen; estrogen receptor; phosphoproteomic; xenoestrogens

Mesh:

Substances:

Year:  2016        PMID: 27026707      PMCID: PMC4880142          DOI: 10.1093/toxsci/kfw057

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  47 in total

1.  Estradiol in vivo regulation of brain mitochondrial proteome.

Authors:  Jon Nilsen; Ronald W Irwin; Timothy K Gallaher; Roberta Diaz Brinton
Journal:  J Neurosci       Date:  2007-12-19       Impact factor: 6.167

2.  The putative G-protein coupled estrogen receptor agonist G-1 suppresses proliferation of ovarian and breast cancer cells in a GPER-independent manner.

Authors:  Cheng Wang; Xiangmin Lv; Chao Jiang; John S Davis
Journal:  Am J Transl Res       Date:  2012-10-10       Impact factor: 4.060

3.  Effect of royal jelly on bisphenol A-induced proliferation of human breast cancer cells.

Authors:  Mako Nakaya; Hiroyuki Onda; Kyoko Sasaki; Akiko Yukiyoshi; Hirofumi Tachibana; Koji Yamada
Journal:  Biosci Biotechnol Biochem       Date:  2007-01-07       Impact factor: 2.043

4.  Estrogenicity of bisphenol A and bisphenol A dimethacrylate in vitro.

Authors:  T E Schafer; C A Lapp; C M Hanes; J B Lewis; J C Wataha; G S Schuster
Journal:  J Biomed Mater Res       Date:  1999-06-05

Review 5.  Phosphoproteomics in cancer.

Authors:  H C Harsha; Akhilesh Pandey
Journal:  Mol Oncol       Date:  2010-09-26       Impact factor: 6.603

6.  GPR30 activation opposes estrogen-dependent uterine growth via inhibition of stromal ERK1/2 and estrogen receptor alpha (ERα) phosphorylation signals.

Authors:  Fei Gao; Xinghong Ma; Alicia B Ostmann; Sanjoy K Das
Journal:  Endocrinology       Date:  2011-02-08       Impact factor: 4.736

7.  Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.

Authors:  Jesper V Olsen; Blagoy Blagoev; Florian Gnad; Boris Macek; Chanchal Kumar; Peter Mortensen; Matthias Mann
Journal:  Cell       Date:  2006-11-03       Impact factor: 41.582

8.  Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF.

Authors:  Deo Prakash Pandey; Rosamaria Lappano; Lidia Albanito; Antonio Madeo; Marcello Maggiolini; Didier Picard
Journal:  EMBO J       Date:  2009-01-15       Impact factor: 11.598

9.  Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta.

Authors:  G G Kuiper; J G Lemmen; B Carlsson; J C Corton; S H Safe; P T van der Saag; B van der Burg; J A Gustafsson
Journal:  Endocrinology       Date:  1998-10       Impact factor: 4.736

10.  Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase.

Authors:  S Kato; H Endoh; Y Masuhiro; T Kitamoto; S Uchiyama; H Sasaki; S Masushige; Y Gotoh; E Nishida; H Kawashima; D Metzger; P Chambon
Journal:  Science       Date:  1995-12-01       Impact factor: 47.728

View more
  9 in total

Review 1.  Anillin is an emerging regulator of tumorigenesis, acting as a cortical cytoskeletal scaffold and a nuclear modulator of cancer cell differentiation.

Authors:  Nayden G Naydenov; Jennifer E Koblinski; Andrei I Ivanov
Journal:  Cell Mol Life Sci       Date:  2020-09-03       Impact factor: 9.261

Review 2.  Crosstalk between nuclear and G protein-coupled estrogen receptors.

Authors:  Shannon N Romano; Daniel A Gorelick
Journal:  Gen Comp Endocrinol       Date:  2017-04-25       Impact factor: 2.822

3.  G-Protein-coupled Estrogen Receptor 1 Agonist G-1 Perturbs Sunitinib Resistance-related Phosphoproteomic Signatures in Renal Cell Carcinoma.

Authors:  Shao-Kuan Chen; Yen-Chieh Wang; Tai-Yuan Lin; Hsin-Jou Wu; Chi-Jung Huang; Wei-Chi Ku
Journal:  Cancer Genomics Proteomics       Date:  2021 May-Jun       Impact factor: 4.069

Review 4.  Phosphoproteomic Analysis as an Approach for Understanding Molecular Mechanisms of cAMP-Dependent Actions.

Authors:  Joseph A Beavo; Martin Golkowski; Masami Shimizu-Albergine; Michael-Claude Beltejar; Karin E Bornfeldt; Shao-En Ong
Journal:  Mol Pharmacol       Date:  2021-02-11       Impact factor: 4.054

5.  Early phosphoproteomic changes for adverse outcome pathway development in the fathead minnow (Pimephales promelas) brain.

Authors:  L C Smith; C M Lavelle; C Silva-Sanchez; N D Denslow; T Sabo-Attwood
Journal:  Sci Rep       Date:  2018-07-05       Impact factor: 4.379

6.  Effects of the selective GPER1 agonist G1 on bone growth.

Authors:  Maryam Iravani; Marie K Lagerquist; Elham Karimian; Andrei S Chagin; Claes Ohlsson; Lars Sävendahl
Journal:  Endocr Connect       Date:  2019-09       Impact factor: 3.335

7.  GPER-induced signaling is essential for the survival of breast cancer stem cells.

Authors:  Yu-Tzu Chan; Alan C-Y Lai; Ruey-Jen Lin; Ya-Hui Wang; Yi-Ting Wang; Wen-Wei Chang; Hsin-Yi Wu; Yu-Ju Lin; Wen-Ying Chang; Jen-Chine Wu; Jyh-Cherng Yu; Yu-Ju Chen; Alice L Yu
Journal:  Int J Cancer       Date:  2019-08-07       Impact factor: 7.396

8.  17β-Estradiol Activates HSF1 via MAPK Signaling in ERα-Positive Breast Cancer Cells.

Authors:  Natalia Vydra; Patryk Janus; Agnieszka Toma-Jonik; Tomasz Stokowy; Katarzyna Mrowiec; Joanna Korfanty; Anna Długajczyk; Bartosz Wojtaś; Bartłomiej Gielniewski; Wiesława Widłak
Journal:  Cancers (Basel)       Date:  2019-10-11       Impact factor: 6.639

9.  Transforming growth factor beta1 targets estrogen receptor signaling in bronchial epithelial cells.

Authors:  L Cody Smith; Santiago Moreno; Lauren Robertson; Sarah Robinson; Kristal Gant; Andrew J Bryant; Tara Sabo-Attwood
Journal:  Respir Res       Date:  2018-08-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.